Clinical Trial Update: A Phase 2, Open-Label Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

This update notes that the Phase 2, open-label study of amuvatinib with platinum-etoposide chemotherapy in small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Amuvatinib (amuvatinib)

Snippet

Sponsor: Astex Pharmaceuticals, Inc. | Conditions: Small Cell Lung Carcinoma | Phase 2 | Status: COMPLETED